EGFR and non-small cell lung carcinoma: A clinical trial comparing osimertinib with pemetrexed plus either carboplatin or cisplatin in patients with EGFR T790M mutation-positive NSCLC and with disease progression after first-line therapy reported significantly longer PFS (10.1 months vs. 4.4 months) and significantly better response rates (71% vs. 31%) with osimertinib [10].